Carmot Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Carmot Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10938
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Carmot Therapeutics Inc (Carmot Therapeutics) is a biotechnology company that discovers and develops drugs for the treatment of cancer, inflammation and metabolic diseases. The company provides product portfolio such as encompasses investigational candidates in preclinical trials: peptide-small molecule hybrid compounds that target Nonalcoholic Steatohepatitis NASH. It offers products such as protein-protein interactions NEMO and IKK for the treatment of cancer and inflammation; and GLP-1R and GIPR for treating Type 2 diabetes and obesity, among others. Carmot Therapeutics proprietary technology, Chemotype Evolution applies to identify and optimize innovative drugs for various therapeutic areas. The company works in collaboration with research institutions and companies such as Amgen Inc and Genentech for discovery of new drugs. Carmot Therapeutics is headquartered in Berkeley, California, the US.

Carmot Therapeutics Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Carmot Therapeutics Raises USD15 Million in Series B Financing 10
Carmot Therapeutics Raises USD10.8 Million in Venture Financing 11
Carmot Therapeutics Raises US$0.5 Million In Venture Financing 12
Licensing Agreements 13
Amgen Enters into Licensing Agreement with Carmot Therapeutics 13
Amgen Expands its Licensing Agreement with Carmot Therapeutics 14
Genentech Enters into Licensing Agreement with Carmot Therapeutics 15
Carmot Therapeutics Inc – Key Competitors 16
Carmot Therapeutics Inc – Key Employees 17
Carmot Therapeutics Inc – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Carmot Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Carmot Therapeutics Raises USD15 Million in Series B Financing 10
Carmot Therapeutics Raises USD10.8 Million in Venture Financing 11
Carmot Therapeutics Raises US$0.5 Million In Venture Financing 12
Amgen Enters into Licensing Agreement with Carmot Therapeutics 13
Amgen Expands its Licensing Agreement with Carmot Therapeutics 14
Genentech Enters into Licensing Agreement with Carmot Therapeutics 15
Carmot Therapeutics Inc, Key Competitors 16
Carmot Therapeutics Inc, Key Employees 17
Carmot Therapeutics Inc, Other Locations 18

List of Figures
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Carmot Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Carmot Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Aben Resources Ltd (ABN):企業の財務及び戦略的SWOT分析
    Summary Aben Resources Ltd. (Aben) is a mineral exploration company that explores and develops gold, silver, uranium and tungsten. The company offers products such as uranium, lithium, gold, silver, lead, zinc and copper. It undertakes projects such as yukon, selwyn recce NWT, mann lake project at e …
  • PJSC Novorossiysk Commercial Sea Port:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' PJSC Novorossiysk Commercial Se …
  • Grupo Grana y Montero SAA (GRAMONC1):企業の財務・戦略的SWOT分析
    Grupo Grana y Montero SAA (GRAMONC1) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • 4P-Pharma SAS:製薬・医療:M&Aディール及び事業提携情報
    Summary 4P-Pharma SAS (4P-Pharma) is a drug development company that offers drug pipeline for cancer and inflammatory diseases. The company’s pipeline product portfolio includes new chemical entities, biologics, added value generics and fixed dose combinations. Its pipeline candidates targets therap …
  • Cyalume Technologies Holdings, Inc.:企業の戦略・SWOT・財務情報
    Cyalume Technologies Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Cyalume Technologies Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Analytik Jena AG (AJA):企業の財務及び戦略的SWOT分析
    Analytik Jena AG (AJA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Crown Energy AB(石油・ガス分野):企業M&A動向
    Summary Crown Energy AB (Crown Energy), is an oil and gas company. It focuses on the acquisition, exploration and development of oil and gas projects located in the under-explored areas. The company has projects located in Equatorial Guinea, South Africa and Madagascar regions. In Equatorial Guinea …
  • Avesthagen Ltd-医療機器分野:企業M&A・提携分析
    Summary Avesthagen Ltd (Avesthagen) is a life science company that offers preventive personalized healthcare solutions. The company offers bio-nutrition, bio-agriculture and bio-pharmaceutical products. Its bio-nutrition products include validated bio-actives from Indian medicinal plants for prevent …
  • Mega International Commercial Bank Co., Ltd.:企業の戦略・SWOT・財務分析
    SummaryMega International Commercial Bank Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ vie …
  • Kite Pharma, Inc. (KITE)(製薬・医療分野):企業M&A動向
    Summary Kite Pharma, Inc. (Kite Pharma) is a biopharmaceutical company. The company discovers and develops innovative immunotherapies for the treatment of cancer. It concentrates on engineered autologous T cell therapy (eACT), designed to restore the patient's immune system, and recognize and eradic …
  • Asseco Poland S.A.:企業のM&A・提携・投資分析
    Asseco Poland S.A. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Asseco Poland S.A. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), d …
  • Jackpot Digital Inc. (JP):企業の財務及び戦略的SWOT分析
    Summary Jackpot Digital Inc. (Jackpot Digital), formerly Las Vegas From Home.com Entertainment, Inc. is a software company that develops and offers online gaming software. The company’s games include poker, Asian multiplayer and casino games. Jackpot Digital offers poker game such as Texas Hold'em, …
  • Alltech Inc:企業の戦略的SWOT分析
    Alltech Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • EndoStim Inc:医療機器:M&Aディール及び事業提携情報
    Summary EndoStim Inc (EndoStim) is a medical device company that provides therapeutic solutions. The company develops and commercializes a neurostimulation system for the treatment of severe gastroesophageal reflux disease. It concentrates on the treatment of gastroesophageal reflux disease through …
  • JX Nippon Oil & Energy Corporation:企業のM&A・提携動向(石油・ガス分野)
    Summary JX Nippon Oil & Energy Corporation (JXNOE) is a downstream refining company. The company refines and markets petroleum and petrochemical products. Its products include petrochemicals, lubricants, optical films, greases, fluids, engine oils, composites, Panaferd-AX, Tow PREPREG, sheet pallet …
  • Homeland Energy Group Ltd. (HEG.H):企業の財務及び戦略的SWOT分析
    Summary Homeland Energy Group Ltd. (Homeland), a subsidiary of GMR Group is a coal production company that acquires, explores, develops and produces mineral resource properties. The company concentrates on properties such as coal production from its existing mines in South Africa. It has operational …
  • Concordia International Rx UK Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Concordia International Rx UK Ltd (Concordia) formerly Amdipharm Mercury Company Ltd, a subsidiary of Concordia International Corp, is a manufacturer of pharmaceutical products and orphan drugs. The company’s products include acetazolamide, adenosine, adrenaline acid tartrate, alfacalcidol, …
  • Virtek Vision International, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Virtek Vision International, In …
  • Southern Pacific Resource Corp.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Southern Pacific Resource Corp. …
  • Goldman Sachs Private Wealth Management:企業の戦略・SWOT・財務情報
    Goldman Sachs Private Wealth Management - Strategy, SWOT and Corporate Finance Report Summary Goldman Sachs Private Wealth Management - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆